Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)

In this trial, we aim to compare the outcomes of adjuvant chemoradiotherapy with chemotherapy for patients with resected pancreatic cancer who are at high risk of disease progressions.

Trial Details

NCT ID

NCT06427447

Phase

PHASE3

Sponsor

Changhai Hospital

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Adjuvant chemoradiotherapy
Adjuvant chemotherapy

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Aged 18-75 years
Pathologically confirmed pancreatic ductal adenocarcinoma
Pathologically confirmed lymph node metastasis, R1 or R2 resection or lymphovascular invasion (one of the risk factors)
No history of cancer treatment after surgical resection

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →